The week in industry: Global rights for brain cancer drug acquired by CNS Pharmaceuticals
This week: First targeted therapy for a sickle cell disease complication approved, collaboration announced to extended to advance cancer therapy development and grant awarded for the development of novel idiopathic pulmonary fibrosis therapeutics.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>